Literature DB >> 23293508

Mesothelioma - Update on Diagnostic Strategies.

Carmen M Rosario1, Xiaoqi Lin, David W Kamp.   

Abstract

Malignant pleural mesothelioma (MPM) can be a challenging diagnosis for clinicians to make as it is often difficult to distinguish from benign asbestos pleural effusions and metastatic carcinomas. In this review, we present a case of MPM and discuss clinical manifestations, traditional diagnostic techniques, and the role of cytopathologic immunostains and serum biomarkers in the diagnosis of MPM.

Entities:  

Year:  2012        PMID： 23293508      PMCID： PMC3536474          DOI： 10.1097/CPM.0b013e318272ce61

Source DB:  PubMed          Journal:  Clin Pulm Med


  42 in total

1.  Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.

Authors:  R T Heelan; V W Rusch; C B Begg; D M Panicek; J F Caravelli; C Eisen
Journal:  AJR Am J Roentgenol       Date:  1999-04       Impact factor: 3.959

2.  Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province.

Authors:  J C WAGNER; C A SLEGGS; P MARCHAND
Journal:  Br J Ind Med       Date:  1960-10

Review 3.  Pathologic evaluation of malignant pleural mesothelioma.

Authors:  Lucian R Chirieac; Joseph M Corson
Journal:  Semin Thorac Cardiovasc Surg       Date:  2009

Review 4.  Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.

Authors:  Masahiro Maeda; Okio Hino
Journal:  Pathol Int       Date:  2006-11       Impact factor: 2.534

Review 5.  Pathological and molecular biological approaches to early mesothelioma.

Authors:  Tohru Tsujimura; Ikuko Torii; Ayuko Sato; Misa Song; Kazuya Fukuoka; Seiki Hasegawa; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

6.  High plasma concentrations of osteopontin in patients with interstitial pneumonia.

Authors:  J Kadota; S Mizunoe; K Mito; H Mukae; S Yoshioka; K Kawakami; Y Koguchi; K Fukushima; S Kon; S Kohno; A Saito; T Uede; M Nasu
Journal:  Respir Med       Date:  2005-01       Impact factor: 3.415

7.  Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.

Authors:  Jenette Creaney; Deborah Yeoman; Yvonne Demelker; Amanda Segal; A W Musk; Steven J Skates; Bruce W S Robinson
Journal:  J Thorac Oncol       Date:  2008-08       Impact factor: 15.609

8.  Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin.

Authors:  Diana M Padgett; Helen P Cathro; Mark R Wick; Stacey E Mills
Journal:  Am J Surg Pathol       Date:  2008-01       Impact factor: 6.394

9.  Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.

Authors:  Bernard Duysinx; Delphine Nguyen; Renaud Louis; Didier Cataldo; Tarik Belhocine; Pierre Bartsch; Thierry Bury
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

10.  Plasma osteopontin levels are associated with the presence and extent of coronary artery disease.

Authors:  Reiko Ohmori; Yukihiko Momiyama; Hiroaki Taniguchi; Rie Takahashi; Masatoshi Kusuhara; Haruo Nakamura; Fumitaka Ohsuzu
Journal:  Atherosclerosis       Date:  2003-10       Impact factor: 5.162
View more
  2 in total

1.  Environmental and Occupational Exposure to Asbestos as a Result of Consumption and Use in Poland.

Authors:  Małgorzata Krówczyńska; Ewa Wilk
Journal:  Int J Environ Res Public Health       Date:  2019-07-22       Impact factor: 3.390

2.  Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells.

Authors:  Vincenza Ciaramella; Carminia Maria Della Corte; Concetta Di Mauro; Stefano Tomassi; Salvatore Di Maro; Teresa Troiani; Erika Martinelli; Roberto Bianco; Sandro Cosconati; Riccardo Pierantoni; Rosaria Meccariello; Rosanna Chianese; Fortunato Ciardiello; Floriana Morgillo
Journal:  Oncotarget       Date:  2018-04-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.